Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment

Recombinant Human Parathyroid Hormone Related Protein 1-34 and 1-84 and Their Roles in Osteoporosis Treatment

Osteoporosis is a common disorder characterized by compromised bone strength that predisposes patients to increased fracture risk. Parathyroid hormone related protein (PTHrP) is one of the candidates for clinical osteoporosis treatment. In this study, GST Gene Fusion System was used to express recombinant human PTHrP (hPTHrP) 1-34 and 1-84. To determine whether the recombinant hPTHrP1-34 and 1-...

Recombinant human parathyroid hormone 1-84 (Natpara)

Description/Mechanism of Action Recombinant human parathyroid hormone (rhPTH 1-84) is identical to endogenous parathyroid hormone (PTH) and binds PTH-1 receptors in the bone, kidney, and has an indirect effect on calcium reabsorption in the intestine. It increases serum calcium by increasing renal tubular calcium reabsorption, intestinal calcium absorption, and bone turnover. Indication under R...

Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.

CONTEXT AND OBJECTIVE Osteoporosis is defined as a disease characterized by low bone mass and deterioration of the bone tissue microarchitecture. Teriparatide stimulates the formation and action of osteoblasts, which are responsible for bone formation, thus promoting bone tissue increase. The aim was to assess the effectiveness and safety of teriparatide for treating postmenopausal osteoporosis...

Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women

OBJECTIVE To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis. SOURCES A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies. STUDY AND DATA SELECTION: Studies were selected according to relevance and availabilit...

1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis.